Evogene (NASDAQ:EVGN) (NASDAQ:EVGN) is a biotechnology company headquartered in Rehovot, Israel, specializing in the development of novel products for agriculture, food ingredients, and human microbiome-based therapeutics. Leveraging its proprietary Computational Predictive Biology (CPB) platform, Evogene integrates large-scale biological data with advanced computational tools to identify and optimize genes, microbial strains, and molecular traits. The company’s core focus encompasses seed traits for crop yield and quality improvement, microbial-based solutions for crop protection and plant health, and discovery of bioactive compounds targeting the human microbiome.
In the agricultural segment, Evogene’s pipeline includes seed trait projects designed to enhance drought tolerance, disease resistance, and nutrient use efficiency in major row crops such as corn, soybean, and canola. Its microbial product candidates aim to offer sustainable alternatives to chemical pesticides and fertilizers by harnessing beneficial bacteria and fungi. On the human health side, Evogene has spun off Biomica, a subsidiary focused on developing microbiome-based therapeutics for conditions such as inflammatory bowel disease and skin disorders, utilizing Evogene’s computational expertise to pinpoint therapeutic strains and bioactive molecules.
The company maintains strategic partnerships and collaborations with leading global agri-businesses and life sciences organizations to accelerate product development and commercialization. Notable collaborators include Bayer Crop Science, Bunge Limited, and International Flavors & Fragrances (IFF), working together on joint research programs and validation trials across North America, South America, Europe, and Asia. These alliances enable Evogene to access diverse field environments and regulatory expertise, positioning its pipeline for broader commercial adoption.
Founded in 2002, Evogene has grown from an academic spin-off into a publicly traded innovator in predictive biology. The leadership team is led by CEO Iris Braun, whose experience spans molecular biology, computational genomics, and product development. Supported by a multidisciplinary staff of computational scientists, molecular biologists, and agronomists, Evogene continues to expand its platform capabilities, aiming to deliver precise, data-driven solutions that address global challenges in agriculture, food security, and human health.
